esophageal motility disorder
Conditions
Interventions
Nifedipine 10 mg CR tablets once daily for 30-60 days, followed by oral endoscopic myotomy
Sponsors
kobayashi Ryosuke
Hirasawa Kingo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Men and women between 18 and 90 years of age at the time of enrollment (2) Patients diagnosed with esophageal achalasia type I, II, III, EGJOO, Distal Esophageal Spasm, Hypercontractile Esophagus based on Chicago Classification v4.0 (3) Patients who give written consent to participate in this study
Exclusion criteria
Exclusion criteria: (1) Patients diagnosed with Absent Conractility, Ineffective Esophageal Motility among esophageal motility disorders (2) Patients with esophageal cancer (3) Patients with a history of hypersensitivity to nifedipine (4) Patients with Cre >2.0 (5) Patients with aortic stenosis, mitral stenosis, pulmonary hypertension, or congestive heart failure (6) Patients with systolic blood pressure less than 100 mmHg (7) Patients originally taking calcium blockers (8) Women who are pregnant, lactating, may become pregnant, or wish to become pregnant during the treatment period (9) Other patients who are judged to be inappropriate for the subject by the physician's judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| p53 positivity in esophageal biopsy specimens before and after intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement rate of p53 positive cells in esophageal biopsies at diagnosis and at POEM Improvement rate of Ki67 positive cells in esophageal biopsies at diagnosis and POEM Improvement rate of Ki67 positive cells at diagnosis and 60-120 days after POEM Percentage improvement in the number of Lugol voiding lesion at diagnosis and 60-120 days after POEM Percentage improvement in ecard score | — |
Contacts
Public ContactDaisuke Azuma
Yokohama City University Medical Center
Outcome results
None listed